NSCLC

Browse all NSCLC
Thoracic Oncology in 2025: Evolving Standards and Practice-Changing Data From ASCO

NSCLC

Thoracic Oncology in 2025: Evolving Standards and Practice-Changing Data From ASCO

Kriti Ahuja, MD

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

NSCLC

Innovación dirigida: datopotamab deruxtecan en el tratamiento del cáncer de pulmón no microcítico avanzado

Coral Olazagasti, MD, Narjust Florez, MD, FASCO

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

NSCLC

Datopotamab Deruxtecan in NSCLC: A Closer Look at TROP2-Targeted Therapy

Coral Olazagasti, MD, Narjust Florez, MD, FASCO

ASCO 2025: Key Clinical Trials in Resectable NSCLC

NSCLC

ASCO 2025: Key Clinical Trials in Resectable NSCLC

Eric Singhi, MD, Mitchell Alexander Parma, MD

SCLC

Browse all SCLC
Small Cell Lung Cancer Takes Center Stage at ASCO 2025

SCLC

Small Cell Lung Cancer Takes Center Stage at ASCO 2025

Eric Singhi, MD, Sandip Patel, MD, FASCO

Lurbinectedin Offers Significant Survival Benefit for Patients With Extensive-Stage SCLC

SCLC

Lurbinectedin Offers Significant Survival Benefit for Patients With Extensive-Stage SCLC

Eric Singhi, MD, Sandip Patel, MD, FASCO

Shifting Paradigms in Lung Cancer Care: Insights From ASCO 2025

SCLC

Shifting Paradigms in Lung Cancer Care: Insights From ASCO 2025

Maria A. Velez, MD, MS